{"disease":{"id":"epstein-barr-virus-associated-lymphoma","name":"epstein barr virus associated lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05978141","title":"A Registry for People With T-cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05011058","title":"An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":102,"lead_sponsor_name":"Viracta Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07381738","title":"Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03397706","title":"Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Viracta Therapeutics, Inc.","has_results":true},{"nct_id":"NCT01805037","title":"Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT07450391","title":"EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Daihong Liu","has_results":false},{"nct_id":"NCT06788600","title":"Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT01964755","title":"Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"University of Miami","has_results":true},{"nct_id":"NCT02822495","title":"Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Atara Biotherapeutics","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}